Dual-time-point 18F-FDG PET/CT versus dynamic breast MRI of suspicious breast lesions

American Journal of Roentgenology

Volumn 191, Issue 5, 2008, Pages 1323-1330

  Imbriaco, Massimo ^a   Caprio, Maria Grazia ^b   Limite, Gennaro ^a   Pace, Leonardo ^a,b   De Falco, Teresa ^b   Capuano, Ermanno ^a   Salvatore, Marco ^a,b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b IRCCS SDN   (Italy)

Author keywords

Breast carcinoma; FDG PET; MRI; PET CT

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GADOLINIUM; GADOLINIUM PENTETATE;

ADULT; ARTICLE; BODY POSTURE; BREAST TUMOR; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

BREAST NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 55549113174     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/AJR.07.3439     Document Type: Article

References (37)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57:43-66
2. Schirrmeister H, Kuhn T, Guhlmann A, et al. Fluorine-18-2-deoxy-2-fluoro- D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med 2001; 28:351-358
3. Eubank WB, Mankoff DA. Evolving role of positron emission tomography in breast cancer imaging. Semin Nucl Med 2005; 35:84-99
4. Matthies A, Hicheson M, Cuchiara A, Alavi A. Dual time point βF-FDG PET for the evaluation of pulmonary nodules. J Nucl Med 2002; 43:871-875
5. Kumar R, Loving VA, Chauhan A, Zhuangh H, Mitchell S, Alavi A. Potential of dual-time-point imaging to improve breast cancer diagnosis with 18F-FDG PET. J Nucl Med 2005; 46:1819-1824
6. 18F-FDG-PET imaging detects breast cancers with high sensitivity and correlates well with histologic subtypes. J Nucl Med 2006; 47:1440-1446
7. Tatsumi M, Cohade C, Mourtzikos KA, Fishman EK, Whal RL. Initial experience with FDG-PET/ CT in the evaluation of breast cancer. Eur J Nucl Med Imaging 2006; 33:254-262
8. Wright H, Listinsky J, Rim A, et al. Magnetic resonance imaging as a diagnostic tool for breast cancer in premenopausal women. Am J Surg 2005; 190:572-575
9. Schnall MD, Blume J, Bluemke DA, et al. Diagnostic architectural and dynamic features at breast MR imaging: multicenter study. Radiology 2006; 238:42-53
10. Lehman CD, Gatsonis C, Kuhl CK, et al. MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med 2007; 356:1295-1303
11. Kuhl CK. Current status of breast MR imaging. Part 2. Clinical applications. Radiology 2007; 244:672-691
12. Morris EA. Diagnostic breast MR imaging: current status and future directions. Radiol Clin North Am 2007; 45:863-880
13. Peters NH, Borel-Rinkes IH, Zuithoff NP, Mali WP, Moons KG, Peeters PH. Meta-analysis of MR imaging in the diagnosis of breast lesions. Radiology 2008; 246:116-124
14. American College of Radiology (ACR). Breast imaging reporting and data system (BI-RADS), 2nd ed. Reston, VA: American College of Radiology, 1995
15. International Commission on Radiological Protection. Radiation dose to patients from radiopharmaceuticals. Publication 80. New York, NY: ICRP, 1998
16. Brix G, Lechel U, Veit R, et al. Assessment of a theoretical formalism for dose estimation in CT: an anthropomorphic phantom study. Eur Radiol 2004; 14:1275-1284
17. Kuhl CK, Schild HH, Morakkabati N. Dynamic bilateral contrast-enhanced MR imaging of the breast: trade-off between spatial and temporal resolution. Radiology 2005; 236:789-800
18. Stack JP, Redmond OM, Codd MB, Dervan PA, Ennis JT. Breast disease: tissue characterization with Gd-DTPA enhancement profiles. Radiology 1990; 174:491-494
19. Kennedy BJ, ed. Manual for the staging of cancer, 4th ed. Philadelphia, PA: Lippincott, 1992
20. Buck A, Schirrmeister H, Kuhn T, et al. FDG uptake in breast cancer correlation with biological and clinical prognostic parameters. Eur J Nucl Med Imaging 2002; 29:1317-1323
21. Lowe VJ, Fletcher JW, Gobar L, et al. Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol 1998; 16:1075-1084
22. Dewan NA, Gupta NC, Redepenning LS, Phalen JJ, Frick MP. Diagnostic efficacy of FDG-PET imaging in solitary pulmonary nodules: potential role in evaluation and management. Chest 1993; 104:997-1002
23. Zhuang H, Pourdehnad M, Lambright ES, et al. Dual time point FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med 2001; 42:1412-1417
24. Hustinx R, Smith RJ, Benard F, et al. Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. Eur J Nucl Med 1999; 26:1345-1348
25. Kumar R, Chauhan A, Zhuang H, Chandra P, Schnall M, Alavi A. Standardized uptake values of normal breast tissue with 2-deoxy-2-[F-18] fluoro-D-glucose positron emission tomography: variations with age, breast density, and menopausal status. Mol Imaging Biol 2006; 8:355-362
26. Hellwig D, Graeter TP, Ukena D, et al. 18F-FDG PET for mediastinal staging of lung cancer: which SUV threshold makes sense? J Nucl Med 2007; 48:1761-1766
27. 18F-FDG uptake and breast density in women with normal breast tissue. J Nucl Med 2004; 45:1423-1424
28. Avril N, Rosè CA, Schelling M, et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol 2000; 18:3495-3502
29. Murthy K, Aznar M, Thompson CJ, Loutfi A, Lisbona R, Gagnon JH. Results of preliminary clinical trials of the positron emission mammography system PEM-I: a dedicated breast imaging system producing glucose metabolic images using FDG. J Nucl Med 2000; 41:1851-1858
30. Tafra L. Positron emission tomography (PET) and mammography (PEM) for breast cancer: importance to surgeons. Ann Surg Oncol 2007; 14:3-13
31. Weinberg IN, Beylin D, Zavarzin V, et al. Positron emission mammography: high-resolution biochemical breast imaging. Technol Cancer Res Treat 2005; 4:55-60
32. Braun M, Polcher M, Schrading S, et al. Influence of preoperative MRI on the surgical management of patients with operable breast cancer. Breast Cancer Res Treat 2008; 111:179-187
33. Buchanan CL, Morris EA, Dorn PL, Borgen PI, Van Zee KJ. Utility of breast magnetic resonance imaging in patients with occult primary breast cancer. Ann Surg Oncol 2005; 12:1045-1053
34. Padhani AR. Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions. J Magn Reson Imaging 2002; 16:407-422
35. Goerres GV, Michel SC, Fehr MK, et al. Follow-up of women with breast cancer: comparison between MRI and FDG-PET. Eur Radiol 2003; 13:1635-1644
36. Heywang SH, Wolf A, Pruss E, Hilbertz TH, Eiermann W, Permanetter W. MR imaging of the breast with Gd-DTPA: use and limitations. Radiology 1989; 171:95-103
37. 18F-FDG PET/CT examinations. J Nucl Med 2005; 46:608-613